Education
About Us
Working with TipRanks
Follow Us
Kenvue, Inc. (KVUE)
NYSE:KVUE
KVUE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$19.75 - $25.17
Previous CloseN/A
Volume2.33M
Average Volume (3M)19.31M
Market Cap
$40.95B
Enterprise Value$47.93B
Total Cash (Recent Filing)$1.06B
Total Debt (Recent Filing)$8.85B
Price to Earnings (P/E)29.0
Beta0.32
Next Earnings
Oct 23, 2025EPS Estimate
0.27Last Dividend Ex-Date
Aug 13, 2025Dividend Yield3.86%
Share Statistics
EPS (TTM)0.29
Shares Outstanding1,919,070,000
10 Day Avg. Volume23,561,720
30 Day Avg. Volume19,309,590
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.17
Enterprise Value/Revenue3.13
Enterprise Value/Gross Profit5.40
Enterprise Value/Ebitda15.68
Forecast
1Y Price Target
$23.83Price Target Upside12.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
Bulls Say, Bears Say
Bulls Say
Brand StrengthKenvue has a strong group of brands and a team to build on, despite the near-term headwinds and uncertainty.
Portfolio PotentialKenvue’s diversified portfolio of leading consumer healthcare brands holds potential for stable and profitable growth.
Bears Say
Earnings ExpectationsPreliminary Q2 sales and earnings results were below expectations, with organic sales at -4.2% compared to the Street’s -1% prior.
Operational ComplexityThe Kenvue portfolio has too much complexity across the organization, including too many SKUs and brands playing across too many countries.
Sales PerformanceSales were below plan, and guidance has been lowered to account for slower category growth rates and soft seasonal business.
Kenvue, Inc. News
KVUE FAQ
What was Kenvue, Inc.’s price range in the past 12 months?
Kenvue, Inc. lowest stock price was $19.75 and its highest was $25.17 in the past 12 months.
What is Kenvue, Inc.’s market cap?
Kenvue, Inc.’s market cap is $40.95B.
When is Kenvue, Inc.’s upcoming earnings report date?
Kenvue, Inc.’s upcoming earnings report date is Oct 23, 2025 which is in 71 days.
How were Kenvue, Inc.’s earnings last quarter?
Kenvue, Inc. released its earnings results on Jul 14, 2025. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.282 by $0.008.
Is Kenvue, Inc. overvalued?
According to Wall Street analysts Kenvue, Inc.’s price is currently Undervalued.
Does Kenvue, Inc. pay dividends?
Kenvue, Inc. pays a Quarterly dividend of $0.207 which represents an annual dividend yield of 3.86%. See more information on Kenvue, Inc. dividends here
What is Kenvue, Inc.’s EPS estimate?
Kenvue, Inc.’s EPS estimate is 0.27.
How many shares outstanding does Kenvue, Inc. have?
Kenvue, Inc. has 1,919,070,000 shares outstanding.
What happened to Kenvue, Inc.’s price movement after its last earnings report?
Kenvue, Inc. reported an EPS of $0.29 in its last earnings report, beating expectations of $0.282. Following the earnings report the stock price went up 2.249%.
Which hedge fund is a major shareholder of Kenvue, Inc.?
Currently, no hedge funds are holding shares in KVUE
Kenvue, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$23.83 (12.30% Upside)
$23.83 (12.30% Upside)
Blogger Sentiment
Bullish
KVUE Sentiment 100%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Increased
By 8.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
4.74%
12-Months-Change
Fundamentals
Return on Equity
13.56%
Trailing 12-Months
Asset Growth
2.61%
Trailing 12-Months
Company Description
Kenvue, Inc.
Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair care, and sun and other care products under the Neutrogena, Aveeno, and OGX brand names. The Essential Health segment offers oral and baby, women's health, and wound care products under the Listerine, Johnson's, Band-Aid, and Stayfree brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey. Kenvue Inc. operates as a subsidiary of Johnson & Johnson.
KVUE Company Deck
KVUE Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Negative
The earnings call highlighted Kenvue's challenges, including disappointing Q2 results, operational complexity, and soft market conditions. However, efforts to strengthen leadership and improve specific brand performances provide some positive outlook. Despite these efforts, the significant challenges and revised guidance indicate a cautious sentiment.View all KVUE earnings summariesKVUE Revenue Breakdown
42.23% Self Care
30.33% Essential Health
27.43% Skin Health and Beauty
KVUE Stock 12 Month Forecast
Average Price Target
$23.83
▲(12.30% Upside)
Technical Analysis
Ownership Overview
1.12% Insiders
35.61% Mutual Funds
0.88% Other Institutional Investors
33.99% Public Companies and Individual Investors